Loading…
Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin‐pump‐treated patients with type 1 diabetes: The Lira Pump trial—a randomized, double‐blinded, placebo‐controlled trial
Aim To investigate the efficacy of adding the glucagon‐like peptide‐1 receptor agonist liraglutide to continuous subcutaneous insulin infusion (CSII) in overweight or obese persons with type 1 diabetes and non‐optimal glycaemic control. Materials and methods A 26‐week, randomized, double‐blind, plac...
Saved in:
| Published in: | Diabetes, obesity & metabolism obesity & metabolism, 2020-04, Vol.22 (4), p.492-500 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3531-689da2ed1cd7f4f5af1f5e70efbaef9b16fa9a1479d264591ed7666e92eda7373 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3531-689da2ed1cd7f4f5af1f5e70efbaef9b16fa9a1479d264591ed7666e92eda7373 |
| container_end_page | 500 |
| container_issue | 4 |
| container_start_page | 492 |
| container_title | Diabetes, obesity & metabolism |
| container_volume | 22 |
| creator | Dejgaard, Thomas F. Schmidt, Signe Frandsen, Christian S. Vistisen, Dorte Madsbad, Sten Andersen, Henrik U. Nørgaard, Kirsten |
| description | Aim
To investigate the efficacy of adding the glucagon‐like peptide‐1 receptor agonist liraglutide to continuous subcutaneous insulin infusion (CSII) in overweight or obese persons with type 1 diabetes and non‐optimal glycaemic control.
Materials and methods
A 26‐week, randomized, double‐blind, placebo‐controlled trial including 44 overweight or obese adults with type 1 diabetes randomized 1:1 to liraglutide 1.8 mg once daily (QD) or placebo added to CSII treatment. The primary endpoint was change in haemoglobin A1c (HbA1c). Secondary endpoints included change in insulin dose, CSII settings, glycaemic variability, body weight and patient‐reported outcome measures. Finally, adverse effects including hypoglycaemic events were registered.
Results
HbA1c was reduced by 5 mmol/mol (0.5%) from a baseline of 66 mmol/mol (8.2%) in patients treated with liraglutide compared with a non‐significant change of +2.3 mmol/mol (0.2%) from a baseline of 66 mmol/mol (8.1%) in patients treated with placebo (between‐group difference 7 mmol/mol [0.7%], P |
| doi_str_mv | 10.1111/dom.13911 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2312803147</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2370740551</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3531-689da2ed1cd7f4f5af1f5e70efbaef9b16fa9a1479d264591ed7666e92eda7373</originalsourceid><addsrcrecordid>eNp1kc1u1DAQxyMEoqVw4AWQJS4gkdaOE2fdGyqf0qJyKOfIiSe7rpw4-INVOPUROPBu3PskzG4KByR8GXv8m_9_NJNlTxk9ZXjOtBtOGZeM3cuOWSl4zngh7h_uRb6StDjKHoVwTSkt-ap-mB1xJqSo5Oo4-7U2Xm1sikYD8aBTB4Fs5wn8xs6dgsEookZNWqdnsgOz2UZiRuK-gV9er4ieg4dNsiqCxr-QrBlvb35MaZgwRA-Hj0lFA2MMZGfilkR0IIxoo1qIEM7J1RbIvhXyGctI9EbZ25ufing0d4P5DhqNXGotoGaLDnqfmazqoHWY6twYvbMWnQ7Fj7MHvbIBntzFk-zLu7dXFx_y9eX7jxev13nHK85ysZJaFaBZp-u-7CvVs76CmkLfKuhly0SvpGJlLXUhykoy0LUQAiTWqJrX_CR7sehO3n1NEGIzmNCBtWoEl0JTcFasKEcFRJ__g1675EfsDqma1iWtKobUy4XqvAs42L6ZvBmUnxtGm_22G5xHc9g2ss_uFFM7gP5L_lkvAmcLsDMW5v8rNW8uPy2SvwHMfL6U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2370740551</pqid></control><display><type>article</type><title>Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin‐pump‐treated patients with type 1 diabetes: The Lira Pump trial—a randomized, double‐blinded, placebo‐controlled trial</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Dejgaard, Thomas F. ; Schmidt, Signe ; Frandsen, Christian S. ; Vistisen, Dorte ; Madsbad, Sten ; Andersen, Henrik U. ; Nørgaard, Kirsten</creator><creatorcontrib>Dejgaard, Thomas F. ; Schmidt, Signe ; Frandsen, Christian S. ; Vistisen, Dorte ; Madsbad, Sten ; Andersen, Henrik U. ; Nørgaard, Kirsten</creatorcontrib><description>Aim
To investigate the efficacy of adding the glucagon‐like peptide‐1 receptor agonist liraglutide to continuous subcutaneous insulin infusion (CSII) in overweight or obese persons with type 1 diabetes and non‐optimal glycaemic control.
Materials and methods
A 26‐week, randomized, double‐blind, placebo‐controlled trial including 44 overweight or obese adults with type 1 diabetes randomized 1:1 to liraglutide 1.8 mg once daily (QD) or placebo added to CSII treatment. The primary endpoint was change in haemoglobin A1c (HbA1c). Secondary endpoints included change in insulin dose, CSII settings, glycaemic variability, body weight and patient‐reported outcome measures. Finally, adverse effects including hypoglycaemic events were registered.
Results
HbA1c was reduced by 5 mmol/mol (0.5%) from a baseline of 66 mmol/mol (8.2%) in patients treated with liraglutide compared with a non‐significant change of +2.3 mmol/mol (0.2%) from a baseline of 66 mmol/mol (8.1%) in patients treated with placebo (between‐group difference 7 mmol/mol [0.7%], P < 0.001). Liraglutide reduced total insulin dose by 8 units/day or 16% of total insulin dose (P = 0.008). Mean body weight was reduced by 6.3 kg (P < 0.001) compared with placebo. Concomitantly, time spent in glycaemic target range 4–10 mmol/L (71–180 mg/dL) increased while the risk of hypoglycaemia did not differ between groups at the end of treatment.
Conclusion
Liraglutide treatment reduced HbA1c, total daily insulin dose and body weight without increasing the risk of hypoglycaemia in CSII‐treated patients with type 1 diabetes and insufficient glycaemic control. Liraglutide may be considered a potential add‐on therapy to insulin in this subgroup of patients.</description><identifier>ISSN: 1462-8902</identifier><identifier>EISSN: 1463-1326</identifier><identifier>DOI: 10.1111/dom.13911</identifier><identifier>PMID: 31696598</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Antidiabetics ; Body weight ; Clinical trials ; Diabetes ; Diabetes mellitus (insulin dependent) ; Drug therapy ; GLP-1 receptor agonists ; Glucagon ; Hemoglobin ; Hyperglycemia ; Hypoglycemia ; Insulin ; Obesity ; Overweight ; Weight control</subject><ispartof>Diabetes, obesity & metabolism, 2020-04, Vol.22 (4), p.492-500</ispartof><rights>2019 John Wiley & Sons Ltd</rights><rights>2019 John Wiley & Sons Ltd.</rights><rights>2020 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3531-689da2ed1cd7f4f5af1f5e70efbaef9b16fa9a1479d264591ed7666e92eda7373</citedby><cites>FETCH-LOGICAL-c3531-689da2ed1cd7f4f5af1f5e70efbaef9b16fa9a1479d264591ed7666e92eda7373</cites><orcidid>0000-0002-0097-7052 ; 0000-0002-6968-6675</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31696598$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dejgaard, Thomas F.</creatorcontrib><creatorcontrib>Schmidt, Signe</creatorcontrib><creatorcontrib>Frandsen, Christian S.</creatorcontrib><creatorcontrib>Vistisen, Dorte</creatorcontrib><creatorcontrib>Madsbad, Sten</creatorcontrib><creatorcontrib>Andersen, Henrik U.</creatorcontrib><creatorcontrib>Nørgaard, Kirsten</creatorcontrib><title>Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin‐pump‐treated patients with type 1 diabetes: The Lira Pump trial—a randomized, double‐blinded, placebo‐controlled trial</title><title>Diabetes, obesity & metabolism</title><addtitle>Diabetes Obes Metab</addtitle><description>Aim
To investigate the efficacy of adding the glucagon‐like peptide‐1 receptor agonist liraglutide to continuous subcutaneous insulin infusion (CSII) in overweight or obese persons with type 1 diabetes and non‐optimal glycaemic control.
Materials and methods
A 26‐week, randomized, double‐blind, placebo‐controlled trial including 44 overweight or obese adults with type 1 diabetes randomized 1:1 to liraglutide 1.8 mg once daily (QD) or placebo added to CSII treatment. The primary endpoint was change in haemoglobin A1c (HbA1c). Secondary endpoints included change in insulin dose, CSII settings, glycaemic variability, body weight and patient‐reported outcome measures. Finally, adverse effects including hypoglycaemic events were registered.
Results
HbA1c was reduced by 5 mmol/mol (0.5%) from a baseline of 66 mmol/mol (8.2%) in patients treated with liraglutide compared with a non‐significant change of +2.3 mmol/mol (0.2%) from a baseline of 66 mmol/mol (8.1%) in patients treated with placebo (between‐group difference 7 mmol/mol [0.7%], P < 0.001). Liraglutide reduced total insulin dose by 8 units/day or 16% of total insulin dose (P = 0.008). Mean body weight was reduced by 6.3 kg (P < 0.001) compared with placebo. Concomitantly, time spent in glycaemic target range 4–10 mmol/L (71–180 mg/dL) increased while the risk of hypoglycaemia did not differ between groups at the end of treatment.
Conclusion
Liraglutide treatment reduced HbA1c, total daily insulin dose and body weight without increasing the risk of hypoglycaemia in CSII‐treated patients with type 1 diabetes and insufficient glycaemic control. Liraglutide may be considered a potential add‐on therapy to insulin in this subgroup of patients.</description><subject>Antidiabetics</subject><subject>Body weight</subject><subject>Clinical trials</subject><subject>Diabetes</subject><subject>Diabetes mellitus (insulin dependent)</subject><subject>Drug therapy</subject><subject>GLP-1 receptor agonists</subject><subject>Glucagon</subject><subject>Hemoglobin</subject><subject>Hyperglycemia</subject><subject>Hypoglycemia</subject><subject>Insulin</subject><subject>Obesity</subject><subject>Overweight</subject><subject>Weight control</subject><issn>1462-8902</issn><issn>1463-1326</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1kc1u1DAQxyMEoqVw4AWQJS4gkdaOE2fdGyqf0qJyKOfIiSe7rpw4-INVOPUROPBu3PskzG4KByR8GXv8m_9_NJNlTxk9ZXjOtBtOGZeM3cuOWSl4zngh7h_uRb6StDjKHoVwTSkt-ap-mB1xJqSo5Oo4-7U2Xm1sikYD8aBTB4Fs5wn8xs6dgsEookZNWqdnsgOz2UZiRuK-gV9er4ieg4dNsiqCxr-QrBlvb35MaZgwRA-Hj0lFA2MMZGfilkR0IIxoo1qIEM7J1RbIvhXyGctI9EbZ25ufing0d4P5DhqNXGotoGaLDnqfmazqoHWY6twYvbMWnQ7Fj7MHvbIBntzFk-zLu7dXFx_y9eX7jxev13nHK85ysZJaFaBZp-u-7CvVs76CmkLfKuhly0SvpGJlLXUhykoy0LUQAiTWqJrX_CR7sehO3n1NEGIzmNCBtWoEl0JTcFasKEcFRJ__g1675EfsDqma1iWtKobUy4XqvAs42L6ZvBmUnxtGm_22G5xHc9g2ss_uFFM7gP5L_lkvAmcLsDMW5v8rNW8uPy2SvwHMfL6U</recordid><startdate>202004</startdate><enddate>202004</enddate><creator>Dejgaard, Thomas F.</creator><creator>Schmidt, Signe</creator><creator>Frandsen, Christian S.</creator><creator>Vistisen, Dorte</creator><creator>Madsbad, Sten</creator><creator>Andersen, Henrik U.</creator><creator>Nørgaard, Kirsten</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0097-7052</orcidid><orcidid>https://orcid.org/0000-0002-6968-6675</orcidid></search><sort><creationdate>202004</creationdate><title>Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin‐pump‐treated patients with type 1 diabetes: The Lira Pump trial—a randomized, double‐blinded, placebo‐controlled trial</title><author>Dejgaard, Thomas F. ; Schmidt, Signe ; Frandsen, Christian S. ; Vistisen, Dorte ; Madsbad, Sten ; Andersen, Henrik U. ; Nørgaard, Kirsten</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3531-689da2ed1cd7f4f5af1f5e70efbaef9b16fa9a1479d264591ed7666e92eda7373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antidiabetics</topic><topic>Body weight</topic><topic>Clinical trials</topic><topic>Diabetes</topic><topic>Diabetes mellitus (insulin dependent)</topic><topic>Drug therapy</topic><topic>GLP-1 receptor agonists</topic><topic>Glucagon</topic><topic>Hemoglobin</topic><topic>Hyperglycemia</topic><topic>Hypoglycemia</topic><topic>Insulin</topic><topic>Obesity</topic><topic>Overweight</topic><topic>Weight control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dejgaard, Thomas F.</creatorcontrib><creatorcontrib>Schmidt, Signe</creatorcontrib><creatorcontrib>Frandsen, Christian S.</creatorcontrib><creatorcontrib>Vistisen, Dorte</creatorcontrib><creatorcontrib>Madsbad, Sten</creatorcontrib><creatorcontrib>Andersen, Henrik U.</creatorcontrib><creatorcontrib>Nørgaard, Kirsten</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes, obesity & metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dejgaard, Thomas F.</au><au>Schmidt, Signe</au><au>Frandsen, Christian S.</au><au>Vistisen, Dorte</au><au>Madsbad, Sten</au><au>Andersen, Henrik U.</au><au>Nørgaard, Kirsten</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin‐pump‐treated patients with type 1 diabetes: The Lira Pump trial—a randomized, double‐blinded, placebo‐controlled trial</atitle><jtitle>Diabetes, obesity & metabolism</jtitle><addtitle>Diabetes Obes Metab</addtitle><date>2020-04</date><risdate>2020</risdate><volume>22</volume><issue>4</issue><spage>492</spage><epage>500</epage><pages>492-500</pages><issn>1462-8902</issn><eissn>1463-1326</eissn><abstract>Aim
To investigate the efficacy of adding the glucagon‐like peptide‐1 receptor agonist liraglutide to continuous subcutaneous insulin infusion (CSII) in overweight or obese persons with type 1 diabetes and non‐optimal glycaemic control.
Materials and methods
A 26‐week, randomized, double‐blind, placebo‐controlled trial including 44 overweight or obese adults with type 1 diabetes randomized 1:1 to liraglutide 1.8 mg once daily (QD) or placebo added to CSII treatment. The primary endpoint was change in haemoglobin A1c (HbA1c). Secondary endpoints included change in insulin dose, CSII settings, glycaemic variability, body weight and patient‐reported outcome measures. Finally, adverse effects including hypoglycaemic events were registered.
Results
HbA1c was reduced by 5 mmol/mol (0.5%) from a baseline of 66 mmol/mol (8.2%) in patients treated with liraglutide compared with a non‐significant change of +2.3 mmol/mol (0.2%) from a baseline of 66 mmol/mol (8.1%) in patients treated with placebo (between‐group difference 7 mmol/mol [0.7%], P < 0.001). Liraglutide reduced total insulin dose by 8 units/day or 16% of total insulin dose (P = 0.008). Mean body weight was reduced by 6.3 kg (P < 0.001) compared with placebo. Concomitantly, time spent in glycaemic target range 4–10 mmol/L (71–180 mg/dL) increased while the risk of hypoglycaemia did not differ between groups at the end of treatment.
Conclusion
Liraglutide treatment reduced HbA1c, total daily insulin dose and body weight without increasing the risk of hypoglycaemia in CSII‐treated patients with type 1 diabetes and insufficient glycaemic control. Liraglutide may be considered a potential add‐on therapy to insulin in this subgroup of patients.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>31696598</pmid><doi>10.1111/dom.13911</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-0097-7052</orcidid><orcidid>https://orcid.org/0000-0002-6968-6675</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-8902 |
| ispartof | Diabetes, obesity & metabolism, 2020-04, Vol.22 (4), p.492-500 |
| issn | 1462-8902 1463-1326 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2312803147 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Antidiabetics Body weight Clinical trials Diabetes Diabetes mellitus (insulin dependent) Drug therapy GLP-1 receptor agonists Glucagon Hemoglobin Hyperglycemia Hypoglycemia Insulin Obesity Overweight Weight control |
| title | Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin‐pump‐treated patients with type 1 diabetes: The Lira Pump trial—a randomized, double‐blinded, placebo‐controlled trial |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T09%3A47%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Liraglutide%20reduces%20hyperglycaemia%20and%20body%20weight%20in%20overweight,%20dysregulated%20insulin%E2%80%90pump%E2%80%90treated%20patients%20with%20type%201%20diabetes:%20The%20Lira%20Pump%20trial%E2%80%94a%20randomized,%20double%E2%80%90blinded,%20placebo%E2%80%90controlled%20trial&rft.jtitle=Diabetes,%20obesity%20&%20metabolism&rft.au=Dejgaard,%20Thomas%20F.&rft.date=2020-04&rft.volume=22&rft.issue=4&rft.spage=492&rft.epage=500&rft.pages=492-500&rft.issn=1462-8902&rft.eissn=1463-1326&rft_id=info:doi/10.1111/dom.13911&rft_dat=%3Cproquest_cross%3E2370740551%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3531-689da2ed1cd7f4f5af1f5e70efbaef9b16fa9a1479d264591ed7666e92eda7373%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2370740551&rft_id=info:pmid/31696598&rfr_iscdi=true |